Interleukin 4 (IL-4) has a variety of immune functions, including helper T-cell (Th-cell) differentiation and innate immune-response processes. However, the impact of IL-4 on gamma delta (cd) T cells remains unclear. In this study, we investigate the effects of IL-4 on the activation and proliferation of cd T cells and the balance between variable delta 1 (Vd1) and Vd2 T cells in humans. The results show that IL-4 inhibits the activation of cd T cells in the presence of cd T-cell receptor (TCR) stimulation in a STAT6-dependent manner. IL-4 promoted the growth of activated cd T cells and increased the levels of Vd1 T cells, which in turn inhibited Vd2 T-cell growth via significant IL-10 secretion. Vd1 T cells secreted significantly less interferon gamma (IFNc) and more IL-10 relative to Vd2. Furthermore, Vd1 T cells showed relatively low levels of Natural Killer Group 2D (NKG2D) expression in the presence of IL-4, suggesting that Vd1 T cells weaken the cd T cell-mediated anti-tumor immune response. For the first time, our findings demonstrate a negative regulatory role of IL-4 in cd T cell-mediated anti-tumor immunity. Cellular & Molecular Immunology
INTRODUCTION
T lymphocytes bearing gamma delta T-cell receptors (cd TCRs) represent a minor population of T lymphocytes in human peripheral blood, and most exhibit the CD3 1 CD4 2 CD8 2 phenotype. 1 cd T cells directly recognize and bind antigens in a manner independent of the major histocompatibility complex and play an important role in immune surveillance and regulation in both innate and adaptive immunity.
2- 5 The cd T cells kill a variety of epithelial tumor cells via secretion of interferon gamma (IFNc), tumor necrosis factor alpha (TNFa), perforin, and granzymes. The cd T cells are also involved in immune surveillance of infection caused by numerous viruses, such as human immunodeficiency virus, Epstein-Barr virus and hepatitis B virus. 6, 7 In humans, cd T cells in peripheral blood are characterized as either Vd1 or Vd2 T cells depending on the d chain used. Of these two subsets, Vd2 T cells respond to inflammation/infection by producing inflammatory cytokines and inducing cytotoxicity in infected host cells. Vd1 cells also regulate the immune response 8, 9 in addition to exerting anti-tumor [10] [11] [12] [13] [14] and anti-viral effects. [15] [16] [17] For example, a dominant Vd1 T-cell population in tumor-infiltrating lymphocytes triggers potent immunosuppression via toll-like receptor 8 signaling. 18 Therefore, the ratio of Vd1 to Vd2 T cells increases in the peripheral blood of tolerant recipients after liver transplantation and in cases of accepted grafts. In contrast, the ratio decreases in cases of chronically rejected grafts and graft recipients unable to cease immunosuppression therapy. [19] [20] [21] In mice, Vc1 cd T cells suppress Vc4 cd T cell-mediated antitumor functions through Interleukin-4 (IL-4) production independent of cell-cell contacts. 22 These results indicate that Vd1 T cells have inhibitory effects on the immune response.
The distinct roles of these two subsets of cd T cells have also been demonstrated in autoimmune disease models and infection and immunity. [23] [24] [25] [26] [27] IL-4 is a glycosylated, type-I cytokine primarily produced by T cells, natural killer T cells, mast cells and eosinophils. IL-4 initiates signal transduction through either the type I or type II receptor. IL-4 signaling is required for the differentiation of helper T 2 (Th2) and Th9 cells and regulates immunoglobulin class switching in B cells. 28, 29 IL-4 also plays a central role in the development of allergic inflammation and asthma by enhancing the expression of the high-affinity IgE receptor Fc epsilon RI on B cells, mast cells and basophils, promoting mast-cell survival and proliferation and inducing chemotaxis in mast cells, basophils and eosinophils.
In humans, IL-4 levels are usually elevated in the microenvironment of tumors, including renal cell cancer, non-small cell lung cancer, prostate cancer, colon cancer and breast cancer. In fact, production of IL-4 may be closely related to the stage and grade of malignancy in cancer patients. 30 IL-4 receptor (IL-4R) is expressed at higher levels in situ in lung, ovarian, breast and pancreatic tumor samples compared with normal tissues. [31] [32] [33] [34] cd T cells have also been identified in many types of tumors. 6, 35 It has been suggested that tumor-derived cd T cells have regulatory effects in addition to typical anti-tumor effects. 36 Breast tumor-derived cd T regulatory cells were shown to induce immunosenescence in targeted naive and effector T cells and dendritic cells. 37 However, it was also reported that patients exhibiting increased circulating Vd1T lymphocytes, high levels of serum IL-4 and high expression of UL16 binding protein (ULBP) showed stable disease in a 1-year follow-up, in contrast to disease progression seen in patients with low circulating Vd1T cells and undetectable IL-4 or ULBPs. 38 It is essential to understand the role of tumor-infiltrating cd T cells in order to effectively design immunotherapies. However, the exact function(s) of the subsets of cd T cells in tumors are largely unknown, especially regarding the potentially suppressive effects of cd T cells. In this study, we assess the effects of IL-4 on the human cd T cell-mediated immune response in order to investigate the relationship between IL-4 and cd T cells in tumor microenvironments.
MATERIALS AND METHODS

Antibodies and reagents
Purified anti-human cd-TCR mAb (IMMU 510), anti-human Vd2-TCR fluorescein isothiocyanate (FITC)-conjugated mAb (IMMU 389) and anti-human Natural Killer Group 2A (NKG2A) phycoerythrin (PE)-conjugated mAb (IM329IU) were obtained from ImmunoTech, Beckman Coulter, Fullerton, CA, USA. Purified anti-TCR Vd1 mAb (TS 8.2) and anti-human Vd1-TCR-FITC mAb (TS 8.2) were from Thermo Scientific, Waltham, MA, USA. Fluorescence-conjugated mAbs to CD212, CD210, CD124, CD152, CD27, NKG2D, CD94, T-bet, Gata3, Foxp3, Stat6, PLC-c1 (pY783), SLP-76 (pY128), ERK1/2 (pT202/pY204), Akt (pS473), IRS-1 (pY896) and PKCh (27/PKCh) were from BD Pharmingen, San Diego, CA, USA. Fluorescence-conjugated mAbs to Vd2-TCR,  IFNc, IL-10, CD3, CD45, Tim-3, TNFa, IL17A, IL-4, MICA/B  and LEAF purified anti-human IL-4, IL-10 and IL-13 mAb were  obtained 
Expansion of cd T cells in vitro
Peripheral blood mononuclear cells (PBMCs) from healthy adult donors were isolated by Ficoll-Hypaque (TBD, Tianjin, China) centrifugation. The expansion of both Vd1 T cells and Vd2 T cells was performed as previously described. 39, 40 Briefly, PBMCs were cultured in complete RPMI 1640 medium supplemented with 2 mM L-glutamine, 10 mM HEPES, 10% FCS and 100 IU/ml rhIL-2 in 48-or 24-well culture plates precoated with immobilized anti-human cd-TCR mAb (1 mg/ ml) for 12-14 d. In some groups, rIL-4 (5 ng/ml), IL-10 or IL-13 was added at the beginning of the culture and replenished every 2 days. To selectively expand Vd1 T cells, PBMCs were expanded with purified anti-TCR Vd1 mAb and cultured in the same medium as described above. To selectively expand Vd2 T cells, PBMCs were stimulated with zoledronic acid (5 mM) or pamidronate disodium (10 mM) and cultured in the same medium as described above. 41 Cell viability was assayed by Trypan Blue exclusion method.
Cell sorting
After 2 weeks in culture, the cd T cells that were expanded with anti-human TCR cd mAb were collected and purified by negative selection using a human TCRc/d 1 T Cell Isolation Kit (Miltenyi Biotec). The purified cd T cells were then divided into two parts and labeled with FITC-conjugated anti-Vd1 TCR or PE-conjugated anti-Vd2 TCR antibody. Anti-FITC MicroBeads or anti-PE MicroBeads were added (Miltenyi Biotec) and magnetically separated using MS columns (Miltenyi Biotec) according to the manufacturer's protocol. We positively selected Vd1 T cells or Vd2 T cells, and negatively enriched Vd2 T cells or Vd1 T cells by the method described above. After 72 h of rest, isolated cd T cells were collected and used for cytotoxicity assays or detection of phosphorylated signaling molecules.
Cytokine detection in supernatants Purified Vd1 T cells (.90%) and Vd2 T cells (.92%) were obtained through magnetic-bead sorting technology and were cultured for 12, 24 and 48 h in 24-well plates. Cell-free supernatants were collected to detect the levels of IFNc, TNFa, IL-4, IL-10, IL-6 and IL-17A using the human ELISA Immunoassay Kit (eBioscience) or the Milliplex human Th17 multiplex panel (Millipore) following the appropriate manufacturer's instructions.
Flow cytometric analysis cd T cells were stained at 4 uC for 10-15 min with the appropriate antibodies. Stained cells were analyzed by flow cytometry on a BD Accuri C6 flow cytometer (Becton Dickinson) using FlowJo Software (Tree Star Inc.).
Intracellular cytokine staining
Cells were activated with phorbol myristate acetate (20 ng/ml) plus ionomycin (1 mg/ml) for 4 h, and monensin was added in the last 2 h of cell-culture activation. Cell-surface staining was performed using FITC-conjugated anti-Vd1 or anti-Vd2 antibody. Subsequently, intracellular IFNc, TNFa, IL-4, IL-10 or IL-17A was stained according to the Intracellular Cytokine Staining protocol (BioLegend).
Detection of phosphorylation cd T cells (.92%) were maintained for 24 h in RPMI 1640 medium containing 0.1% serum. To activate cd-TCR signaling, cd T cells were stimulated with immobilized anti-human cd-TCR mAb (1 mg/ml) for 5 min in RPMI 1640 medium at 37 uC. To activate cytokine-induced signaling, cd T cells were transferred to RPMI 1640 containing IL-2 (100 ng/ml) or IL-4 (100 ng/ml), or IL-2 plus IL-4 for 10 to 45 min at 37 uC. At the end of the treatment, one volume of the warmed BD Phosflow Fix Buffer I was immediately mixed with one volume of the PBMC suspension from treated and untreated samples and mixed well, and the tubes were incubated in a 37 uC water bath for 10 min. After fixation and washes, cells were permeabilized by slowly adding cold BD Phosflow Perm Buffer III while vortexing. Cells were incubated on ice for 30 min, washed and resuspended in 100 ml Stain Buffer (FBS) at 1310 7 cells/ml. The treated and untreated cd T cells were stained with antibody for 1 h. Stained cells were acquired by flow cytometry on a BD Accuri C6 flow cytometer (Becton Dickinson) and analyzed using FlowJo Software (Tree Star Inc.).
Ca
21 flux analysis cd T cells (.92%) were maintained for 24 h in RPMI 1640 medium containing 0.1% serum and were then loaded with 2 mM Fluo-4 AM (Invitrogen) for 45 min at room temperature in HBSS. After washing and resuspending in 200 mL HBSS, cd T cells were seeded on Lab-Tek glass chamber slides (Nunc, Roskilde, Denmark) pre-coated with immobilized anti-human TCR cd mAb (1 mg/ml). Changes in fluorescence are shown as a function of time.
Cytotoxicity assay
The cytotoxicity activity of Vd1 T cells and Vd2 T cells was quantitatively measured by CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega) based on the colorimetric detection of the released lactate dehydrogenase. MGC 803, K562 or G401 was co-cultured with cd T cells at ratios of effector cells to target cells (E/T) of 20 : 1 and 40 : 1. After 6 h, the culture supernatant was used to detect lactate dehydrogenase activity according to the manufacturer's instructions.
CFSE assay
Autologous fresh PBMCs were labeled with CFSE and used as the responder cells, which were cultured in the lower chamber of a Transwell plate pre-coated with immobilized anti-human TCR cd mAb (1 mg/ml). Purified Vd1 T cells (.90%) and Vd2 T cells (.92%) obtained through magnetic bead sorting were used as effector cells and placed in the upper chamber. The ratio of effector cells to responder cells was 3 : 7. After a 10-day incubation, the percentage of Vd2 T cells was analyzed by flow cytometry.
RNA interference and DNA transfection
For RNA interference, cd T cells were transfected with 300 pmol of SignalSilence Stat6 siRNAII (Cell Signaling) using an Amaxa Nucleofector system. A total of 2310 7 cells were resuspended in 100 ml of Amaxa Kit solution V, mixed with siRNA and immediately transfected using program I-24. Cells were incubated for 48 h at 37 uC and 5% CO 2 , with the last 24 h used for resting before the assays were performed as indicated. The negative siRNA control was obtained from Invitrogen.
Statistical analysis
The results are expressed as the mean6s.d. Statistical significance was analyzed by two-tailed unpaired Student's t-test using GraphPad Prism 5 for Windows (GraphPad, San Diego, CA, USA). Throughout the text, figures, and legends, the following terminology is used to show statistical significance: *P,0.05, **P,0.01 and ***P,0.001. (Figure 1d ). IFNc was significantly reduced from approximately 3 ng/ml to ,100 pg/ml after IL-4 treatment. However, the level of IL-10, an antiinflammatory cytokine, was higher than in the absence of IL-4 treatment (Figure 1d ). These results, taken together, suggest that IL-4 inhibits the activation of both Vd1 and Vd2 T cells in vitro.
RESULTS
IL-4 inhibits the activation of both Vd1 and Vd2 T cells in vitro
IL-4 inhibits cd T-cell activation by suppressing the phosphorylation of SLP76, PLCc1 and Erk1/2 and by suppressing Ca 21 release We studied the mechanism of the inhibitory effect of IL-4 on cd T-cell activation. Given that IL-13 has little effect on the activation of cd T cells (data not shown), we speculated that IL-4 function is mediated by type I IL-4 receptor but not type II receptor. The former consists of the two subunits IL-4Ra1 and cc chain, whereas the latter consists of the two subunits IL4Ra1 and IL-13Ra1. Therefore, this study focused on the signals mediated by type I IL-4 receptor. We detected the effect of IL-4 on the phosphorylation status of important signaling molecules for cd T-cell activation. The data show that IL-4 triggered phosphorylation of Stat5 and Stat6 (Figure 2a and b), but not P38 MAPK, Erk1/2, Stat1, Stat3, PKCh, Akt, PLCc1, SLP76 or IRS-1 (data not shown). This result is consistent with previous studies showing IL-4Ra1 mediates the phosphorylation of Stat6, and cc chain (also a subunit of IL-2R) mediates the phosphorylation of Stat5. To further investigate the mechanism of the inhibitory effect of IL-4 on cd T cells, we analyzed the phosphorylation status of important TCR signaling molecules using the BD Phosflow assay, and we measured the levels of Ca 21 by laser confocal microscopy when cd T cells were activated in the presence or absence of IL-4. The results show that TCR stimulation quickly triggered the phosphorylation of (Figure 4a and b) . Furthermore, the effect of IL-4 was dose-dependent (Figure 4b ). These results taken together indicate IL-4 promotes the proliferation of Vd1 T cells.
IL-4 induced Vd1 T-cell bias via IL-10
The above results show that IL-4 promoted Vd1 T cell growth and inhibited Vd2 T-cell growth, resulting in a shift in the cellular balance toward Vd1 T cells. However, this result contradicts other results in our study that show that IL-4 promoted the proliferation of activated Vd2 T cells. In order to explain this phenomenon, we proposed a hypothesis that Vd1T cells directly inhibit the proliferation of Vd2T cells. cells were directly inhibited by the proliferation of Vd2T cells. This inhibitory effect was not dependent on direct cell-cell contact, but rather, was mediated by certain soluble factors (Figure 5a ). The CFSE assay results demonstrate that Vd1 T cells in the upper chamber inhibited Vd2 T-cell growth in the lower chamber (Figure 5b ). In order to investigate which factors play an inhibitory role, anti-IL-10, anti-IL-13 and antiTGFb antibodies were detected in our experimental system. The results of cytokine blocking experiments show that only the addition of anti-IL-10 antibody blocked IL-4-mediated Vd1-T-cell bias; anti-IL-13 and anti-TGFb antibody had no effect ( Figure 5c ). As expected, we observed that IL-10 inhibited the activation and proliferation of Vd2 T cells (Figure 5d and e), while the effect of IL-10 on Vd1 T cells was very weak (data not shown). To determine if Vd1 T cells are the main source of inhibitory cytokine IL-10, Vd1 and Vd2 T cells were sorted by magnetic beads to examine IL-10 secretion. The results show that IL-10 levels in the rested and activated Vd1 T cells were significantly higher compared with Vd2 T cells (Figure 5f ). Furthermore, IL-4 induced CD210 expression in activated Vd2 T cells, while CD210 expression on activated Vd1 T cells did not change significantly after IL-4 treatment. IL-4 induced expression of CD124 on activated Vd1 T cells. However, CD124 expression on activated Vd2T cells was not significantly affected after IL-4 treatment (Figure 5g and h) on the CD124 and CD210 expression of Vd1 and Vd2 T cells and the contribution to the balance of cd T cells and to the Vd1 T cell bias.
IL-4-induced Vd1 T-cell bias weakened the overall immune response of cd T cells
To confirm the biological significance of Vd1 T-cell bias, we analyzed the cytokines, transcription factors and killing function of these two cell populations. The results show significant differences in the cytokine secretion spectrum between Vd1 and Vd2 T cells. Of the 10 cytokines detected, Vd1 T cells secreted a high level of IL-10 and a small amount of IFNc (approximately 400 pg/ml) and TNFa (approximately 70 pg/ ml). Other cytokines were all below the detection limit. Vd2 T cells secreted high levels of IFNc (3 ng/ml) and TNFa (approximately 600 pg/ml), a normal amount of IL-4 (90 pg/ml) and IL-5 (300 pg/ml), but nearly no IL-10 was detected (Figure 5f and 6a). The intracellular staining signal of IFNc and TNFa in Vd2 T cells was stronger than that of Vd1 T cells (Figure 6b ). In order to determine the characteristic transcription factor expression patterns for Vd1 T cells and Vd2 T cells, three specific T-cell transcription factors (T-bet, Gata3 and IL-4 inhibited the expression of NKG2D on Vd1 T cells NKG2D receptor plays an important role in protecting the host from infection and cancer. NKG2D provides a powerful costimulus for the activation of cd T cells. 42, 43, [45] [46] [47] [48] Here, NKG2D expression on cd T cells was detected by flow cytometry. The results show that nearly all activated Vd2 T cells expressed the NKG2D receptor. In comparison, some Vd1 T cells were NKG2D 2 after activation. Furthermore, IL-4 significantly inhibited the expression of NKG2D on Vd1 T cells both in the activation and proliferative stages (Figure 7) . Therefore, we hypothesize that the inhibition of NKG2D by IL-4 reduced the anti-tumor function of Vd1 T cells. DISCUSSION IL-4 promotes Th2 and Th9 differentiation, B-cell proliferation, and mast cell survival and proliferation. cd T cells play important roles in targeting a broad spectrum of tumors, including major histocompatibility complex-unrestricted recognition, abundant IFNc secretion and potent cytotoxicity. 6 In this study, we revealed a critical negative regulatory role of IL-4 in the cd T cell-mediated immune response.
One of the most striking findings in this study was that IL-4 significantly inhibited the phosphorylation of the key signaling molecules SLP76, PLCc1 and Erk1/2 in the TCR signaling pathway and inhibited the release of Ca 21 were not significantly altered. These changes in IL-4R and IL-10R amplified the effect of IL-4 on Vd1 T cells and the effect of IL-10 on Vd2 T cells and subsequently led to a bias toward Vd1 T cells. IL-4 also suppressed NKG2D expression on Vd1 T cells. This finding is similar to previous results showing that IL-4 downregulated NKG2D expression on human CD8 1 T and natural killer cells and suppressed anti-tumor immune responses. [49] [50] [51] In our previous study, we demonstrated that CD27 1 CD25 high Vd1 T cells have a regulatory function. 40 We plan to further compare the functions of NKG2D 2 Vd1 T cells and NKG2D
1
Vd1 T cells to examine whether the NKG2D 2 Vd1 T cells have regulatory effects.
We compared characteristic cytokines, surface molecules, transcription factors and the cytolysis functions of Vd1 T cells and Vd2 T cells to examine Vd1 T cell bias. Vd1 T cells characteristically produced high levels of IL-10 and only a small amount of IFNc and TNFa. Vd2 T cells secreted high levels of IFNc and TNFa, as well as IL-4 and IL-5, although nearly no IL-10 was detected. For the cell-surface phenotypes, almost all activated Vd2T cells expressed NKG2D receptors. However, there was still a substantial population of NKG2D-negative Vd1 T cells after activation. In addition, Vd2 T cells expressed significantly higher CD94/NKG2A and TIM-3 molecules than Vd1 T cells (data not shown).
Both human CD94/NKG2A and TIM-3 are inhibitory receptors expressed by natural killer cells or a subset of T cells and provide a negative feedback signal to suppress excessive immune responses. In this regard, our understanding is that Vd2 T cells have a strong immune function via expression of inhibitory receptors that initiate a negative feedback to avoid excessive immunization. For characteristic transcription factors, both cells expressed T-bet, although more was expressed in Vd2 T cells. Neither cell type expressed Gata3 or Foxp3. However, He et al. 52 detected the expression of Foxp3, which suggests that IL-4 may have a pro-inflammatory effect on Vd1 T cells. The molecular basis for the secretion of IFNc by cd T cells, especially Vd2 T cells, is potentially due to a high level of T-bet expression and absence of GATA-3. The paucity of IL-4 synthesis in these cells is likely secondary to the low level of GATA-3 expression. These results indicate that Vd2 T cells represent common cd T cells with strong immune function, while Vd1 T cells may have inhibitory effects on immune response. TCR and NKG2D are involved in tumor recognition of cd T cells. IFNc is the critical mediator in the protective immune response and has been widely used in many anticancer therapies. Considering Vd1 T cells secreted much less IFNc and more IL-10, and only part of Vd1 T cells were NKG2D 1 Vd1 T cells, it was expected that Vd1 T cells were significantly weaker than Vd2 T cells in killing tumor cells.
In summary, IL-4 directly inhibited the activation of cd T cells at the beginning of the immune response and then increased the number and ratio of the Vd1 T cell subset and decreased the number and ratio of the Vd2 T cell subset in all cd T cells. Finally, IL-4 continued to play an indirect inhibitory role on cd T cells through Vd1 T cells. Therefore, IL-4 suppressed the immune function of cd T cells from the activation phase through the effector phase, resulting in compromised specific cytotoxicity and IFNc secretion in vitro.
IL-4 and IL-2 have been used previously to stimulate the activation and proliferation of cd T cells. It should be noted that these proliferated cells were used as efficient effectors against tumor targets both in vitro and in vivo. For example, Dokouhaki et al. 53 cultured CD4 2 CD8 2 depleted PBMC from 14 healthy individuals in the presence of rhIL-2 and at a low concentration of rhIL-4 (0.1 ng/ml) plus anti-CD3 mAb for 10-14 days. The ex vivo expanded cd T cells expressed high levels of TRAIL, NKG2D, perforin and granzyme B and were induced to produce TNFa and IFNc. Furthermore, these cd T cells had potent anti-tumor effects in vitro against cell lines of both hematological and epithelial origin and significantly inhibited the growth of lung cancer in a mouse xenograft model. 53 This method involves the expansion of both Vd1 and Vd2 T cells. However, it is not clear whether the anti-tumor effect results primarily from the Vd1 or Vd2 T-cell subset, or both. Siegers et al. 54, 55 showed that fresh peripheral blood cd T cells treated with Concanavalin A and 10 ng/ml of human IL-2 and IL4 yielded higher percentages of Vd1 compared with Vd2 T cells in mixed cultures independent of day 0 subset levels in the blood. Concanavalin A exposure (leading to the apoptosis of Vd2 cells), the result demonstrates that the inhibitory effect of IL-4 can be surpassed by IL-2 stimulation, as these Vd1 cellenriched cultures were highly cytotoxic against MEC-1, a human CLL cell line, and PC-3M, a human prostate cancer cell line. These data support IL-4 as a proliferator of cd T cells. In addition, IL-4 has a 'protective' role on Vd1 T cells by preventing activation-induced cell death. 55 A previous study showed that after being challenged by neuroblastoma cells, propagating Vd1 but not Vd2 T cells supported an anti-tumor response by the secretion of pro-inflammatory cytokines. Furthermore, Vd1 T cells did not sustain a growth-promoting or tolerogenic microenvironment in contrast to other cell types. 56 Tumor microenvironment includes multiple innate and adaptive immune cells and soluble factors that, together with tumor and tissue components, regulate tumor formation, progression and metastasis. Cytokines are the critical soluble factors that influence anti-tumor immunity. 57 Among these cytokines, IL-4 has both protective as well as suppressive effects on anti-tumor immune responses depending on its sources, phases and doses, as well as the molecular and cellular environments. Fundamentally understanding the relationship between IL-4 and the compromised immune response of cd T cells is critical for the development of effective strategies for antitumor immunotherapy. This article describes the mechanism of action of IL-4 regulation of the cd T-cell immune response. This subject is not only conducive to a comprehensive understanding of the biological role of cd T cells, but it is also helpful to guide potential cd T cell-based biological therapies.
